Polymer-von Willebrand factor-conjugates
US8357779B2 · kind B2 · utility
Assignees
Inventors
Key dates
| Filing date | Nov 28, 2011 |
| Grant date | Jan 22, 2013 |
| Priority date | — |
| Expiry date | Nov 28, 2031 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K14/775
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention relates to a proteinaceous construct (also designated as polymer-VWF-conjugate) comprising plasmatic and/or recombinant von Willebrand factor (VWF), said VWF being bound to at least one physiologically acceptable polymer molecule, as well as to a complex between said proteinaceous construct and at least one factor VIII (FVIII) protein. The physiologically acceptable polymer molecule can be, for instance, polyethylene glycol (PEG) or polysialic acid (PSA). Further the present invention relates to methods for prolonging the in vivo-half-life of VWF or FVIII in the blood of a mammal having a bleeding disorder associated with functional defects of or deficiencies of at least one of FVIII or VWF.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.